Clarient, Inc. (Nasdaq: CLRT) $2.35. Today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.
What They Do: Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer.
Cell Therapeutics (Nasdaq: CTIC) $1.11. Today announced that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines. The results were presented in a paper titled "Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile," by Laura Gatti et al. that was published in the online edition of the journal Molecular Pharmaceutics. Platinum-based compounds, such as cisplatin and oxaliplatin, are the cornerstone in the treatment of testicular, ovarian, colorectal, lung and other cancers but their effectiveness is limited by the relatively low therapeutic ratio, the ratio of the maximally tolerated dose of the drug to the effective dose, and the frequent occurrence of drug resistance leading to cancer recurrence. The novel bis-platinum compounds represent a completely new class of platinum-based drugs called bisplatinates.
What They Do: CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.
Theravance, Inc. (Nasdaq: THRX) $13.13. Today announced that the European Medicines Agency (EMEA) has completed the validation phase for the Marketing Authorization Application (MAA) for telavancin, a bactericidal, once-daily injectable lipoglycopeptide antibiotic, for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia, and complicated skin and soft tissue infections (cSSTI) in adults. Astellas Pharma Europe B.V., a European affiliate of Astellas Pharma Inc. (Astellas), submitted the MAA in October 2009 under the Centralized Procedure and applied for marketing authorization for telavancin in the Member States of the European Union (EU), plus Iceland, Liechtenstein and Norway. The successful completion of the validation phase for a MAA signifies that the submission is administratively complete and that EMEA's scientific review process has begun.
What They Do: Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates.
Cardiac Science Corporation (Nasdaq: CSCX) $2.09. Today announced a partnership with eClinicalWorks, a leading provider of EMR systems. As a result of this partnership, 30,000 eClinicalWorks physician users across 5,000 medical practices now have the ability to connect their Quinton and Burdick ECG, cardiac stress test, and Holter systems with the eClinicalWorks EMR. Similarly, Cardiac Science's installed customer base of more than 65,000 diagnostic monitoring devices can connect with eClinicalWorks and be assured the test results will flow smoothly into the medical record system.
What They Do: Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
